The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study

2012 ◽  
Vol 54 (4) ◽  
pp. 708-713 ◽  
Author(s):  
Julie M. Vose ◽  
Jonathan W. Friedberg ◽  
Edmund K. Waller ◽  
Bruce D. Cheson ◽  
Vasthala Juvvigunta ◽  
...  
Keyword(s):  
Single Dose ◽  
Phase I ◽  
Hodgkin Lymphoma ◽  
Dose Escalation ◽  
Open Label ◽  
Dose Escalation Study ◽  
Non Hodgkin Lymphoma ◽  
Bi 2536

Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 8505-8505 ◽  
Author(s):  
Andres Forero-Torres ◽  
Craig Moskowitz ◽  
Ranjana H. Advani ◽  
Bijal D. Shah ◽  
Ana Kostic ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Dose Escalation ◽  
Interim Analysis ◽  
Phase 1 ◽  
Open Label ◽  
Dose Escalation Study ◽  
Non Hodgkin Lymphoma ◽  
Label Dose ◽  
B Lineage

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

2014 ◽  
Vol 32 (6) ◽  
pp. 1246-1257 ◽  
Author(s):  
Nizar M. Tannir ◽  
Andres Forero-Torres ◽  
Radhakrishnan Ramchandren ◽  
Sumanta K. Pal ◽  
Stephen M. Ansell ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Hodgkin Lymphoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Dose Escalation ◽  
Renal Cell ◽  
Dose Escalation Study ◽  
Non Hodgkin Lymphoma
Sign in / Sign up

Export Citation Format

Share Document